ZILEUTON ( DrugBank: Zileuton )

3 diseases

85. 特発性間質性肺炎

臨床試験数 : 598 / 薬物数 : 435 - (DrugBank : 116) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 210

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00262405 (ClinicalTrials.gov)	January 2001	12/9/2005	Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis	Phase II Trial of Zileuton Compared to Azathioprine/Prednisone for the Treatment of Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: zileuton;Drug: azathioprine/prednisone	University of Michigan	National Institutes of Health (NIH)	Completed	35 Years	80 Years	Both	44	Phase 2	United States

臨床試験数 : 36 / 薬物数 : 72 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 111

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-015895-87-NL (EUCTR)	23/12/2009	01/10/2009	Application of zileuton (Zyflo CR) in patients with Sjögren Larsson Syndrome - Zileuton in Sjögren Larsson Syndrome	Application of zileuton (Zyflo CR) in patients with Sjögren Larsson Syndrome - Zileuton in Sjögren Larsson Syndrome	Sjögren Larsson syndrome (SLS) is an autosomal recessive inherited neurometabolic disorder which is characterized by a clinical triad of congenital ichthyosis, spastic di- or tetraplegia and mental retardation. A disturbance of lipid metabolism due to deficiency of the microsomal fatty aldehyde dehydrogenase (FALDH) underlies SLS.	Trade Name: Zyflo CR Product Name: zileuton INN or Proposed INN: ZILEUTON Other descriptive name: lipoxygenase inhibitor	UMC St Radboud	NULL	Not Recruiting			Female: yes Male: yes	20	Phase 3	Netherlands

臨床試験数 : 15 / 薬物数 : 57 - (DrugBank : 34) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00467831 (ClinicalTrials.gov)	April 2007	28/4/2007	Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome	Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome	Hermansky-Pudlak Syndrome (HPS);Pulmonary Fibrosis;Oculocutaneous Albinism;Platelet Storage Pool Deficiency;Metabolic Disease	Drug: Losartan;Drug: Zileuton;Drug: N-Acetylcysteine;Drug: Pravastatin;Drug: Erythromycin	National Human Genome Research Institute (NHGRI)	NULL	Terminated	18 Years	70 Years	All	3	Phase 1/Phase 2	United States